PMA device
SIR-Spheres microspheres
Sirtex Medical, Inc. · Microspheres Radionuclide (NAW, Class III) · First FDA decision Mar 5, 2002, newest Mar 24, 2017Liver disease and liver cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
33
Naming "SIR-Spheres"
MAUDE reports
49
Brand "SIR-Spheres", since 2015
PubMed studies
152
Mentioning "SIR-Spheres"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SIR-Spheres microspheres
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- SIR-Spheres microspheresPMA supplement
P990065-S009 · Decided Mar 24, 2017 · 228 days after receipt · Normal 180 Day Track No User Fee
Device type: Microspheres radionuclide (NAW) · Radiology & Imaging
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "SIR-Spheres", any status and sponsor, newest update first.
- SIRT With Tremelimumab and Durvalumab for Resectable HCCActive, not recruiting
Jiping Wang, MD, PhDAcademic, hospital or other
NCT05701488 · 20 participants · Start Apr 21, 2023 · Primary completion Oct 1, 2027
Device: SIRT · For: Resectable Hepatocellular Carcinoma; Hepatocellular Carcinoma; Hepatocellular Cancer
Sites: Los Angeles, California; Boston, Massachusetts · 3 sites in all
32 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SIR-Spheres", and for the whole product code for context.
This brand
49 reports: 7 malfunction, 29 injury, 13 death
Whole product code NAW
540 reports: 29 malfunction, 349 injury, 126 death
Newest reports for this brand
- SIR-SPHERES MICROSPHERESInjury
9710358-2026-00008 · Received Mar 24, 2026 · Event dated Feb 20, 2026
Device type: Microspheres Radionuclide (NAW)
Device problem as coded: No Apparent Adverse Event
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "SIR-Spheres"[tiab]. The summary above synthesizes these.
- SIR-Spheres Activity Measurements Reveal Systematic Miscalibration.
Graves SA, Martin M, Tiwari A, et al. · J Nucl Med · 2022
- 90Y SIR-Spheres Activity Measurement with New SIROS D-Vial Delivery Kit.
Lopez BP, Kappadath SC · J Nucl Med Technol · 2024
- EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.
Weber M, Lam M, Chiesa C, et al. · Eur J Nucl Med Mol Imaging · 2022Practice Guideline
- Gateways to clinical trials.
Tomillero A, Moral MA · Methods Find Exp Clin Pharmacol · 2009Bibliography
- Retrospective SPECT/CT dosimetry following transarterial radioembolization.
Thompson BC, Dezarn WA · J Appl Clin Med Phys · 2021
- Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases.
Aranda E, Aparicio J, Bilbao JI, et al. · Future Oncol · 2017Review
- MIRD Pamphlet No. 29: MIRDy90-A 90Y Research Microsphere Dosimetry Tool.
Marquis H, Ocampo Ramos JC, Carter LM, et al. · J Nucl Med · 2024
- Posttreatment Exposure Rates for 90Y-Microsphere Patients: A Comparison of Products.
Blum S, Silvestrini E, Weinstein J, et al. · J Nucl Med Technol · 2023
- Safety of repeated yttrium-90 radioembolization.
Lam MG, Louie JD, Iagaru AH, et al. · Cardiovasc Intervent Radiol · 2013
- 99m Tc-Macroaggregated Albumin Liver Lung Shunt Study With Uptake Indicative of Patent Falciform Artery.
Namous N, Kushner D, Dadparvar S · Clin Nucl Med · 2023
- Feasibility of Liver Transplantation after 90 Y Radioembolization: Lessons from a Radiation Protection Incident.
Soret M, Maisonobe JA, Maksud P, et al. · Health Phys · 2024Case Reports
Other devices of this type
Also filed under product code NAW.
- TheraSphereBoston Scientific Corporation · PMA 2026
- SIR-Spheres Y-90 resin microspheresSirtex Medical, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.